Prognostic Factors for Visual Outcomes Following the First Episode of NMOSD-Related Optic Neuritis in Affected Eyes

References

• Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17:1019–1032. doi:10.1111/j.1468-1331.2010.03066.x
   PubMed Web of Science ®Google Scholar
• Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2013;261:1–16.
   Web of Science ®Google Scholar
• Sherman E, Han M. Acute and chronic management of neuromyelitis optica spectrum disorder. Curr Treat Options Neurol. 2015;17(11):48. doi:10.1007/s11940-015-0378-x
   PubMed Web of Science ®Google Scholar
• Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology. 2005;64:804–810. doi:10.1212/01.WNL.0000152873.82631.B3
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical characteristics, course and prognosis of relapsing devic’s neuromyelitis optica. J Neurol. 2004;251:47–52. doi:10.1007/s00415-004-0271-0
   PubMed Web of Science ®Google Scholar
• Wingerchuk D, Hogancamp W, O’Brien P, et al. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53:1107–1114. doi:10.1212/WNL.53.5.1107
   PubMed Web of Science ®Google Scholar
• Wingerchuk D, Weinshenker B. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003;60:848–853. doi:10.1212/01.WNL.0000049912.02954.2C
   PubMed Web of Science ®Google Scholar
• Kitley J, Leite M, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135:1834–1849. doi:10.1093/brain/aws109
   PubMed Web of Science ®Google Scholar
• Akaishi T, Nakashima I, Takeshita T, et al. Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. J Neuroimmunol. 2016;293:28–33. doi:10.1016/j.jneuroim.2016.02.004
   PubMed Web of Science ®Google Scholar
• Hansapinyo L, Vivattanaseth C. Clinical characteristics, treatment outcomes and predictive factors in optic neuritis. Open J Ophthalmol. 2018;12:247–255. doi:10.2174/1874364101812010247
   Google Scholar
• Wingerchuk D, Banwell B, Bennett J, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189. doi:10.1212/WNL.0000000000001729
   PubMed Web of Science ®Google Scholar
• Song H, Zhou H, Yang M, et al. Different characteristics of aquaporin-4 and myelin oligodendrocyte glycoprotein antibody-seropositive male optic neuritis in China. J Ophthalmol. 2019;2019:1–7. doi:10.1155/2019/1429548
   Web of Science ®Google Scholar
• Grover S, Fishman G, Anderson R, et al. Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. Ophthalmology. 1999;106(9):1780–1785. doi:10.1016/S0161-6420(99)90342-1
   PubMed Web of Science ®Google Scholar
• McAnany J, Genead M, Walia S, et al. Visual acuity changes in patients with leber congenital amaurosis and mutations in CEP290. JAMA Ophthalmol. 2013;131(2):178–182. doi:10.1001/2013.jamaophthalmol.354
   PubMed Web of Science ®Google Scholar
• Bruscolini A, Sacchetti M, La Cava M, et al. Diagnosis and management of neuromyelitis optica spectrum disorders - An update. Autoimmun Rev. 2018;17:195–200. doi:10.1016/j.autrev.2018.01.001
   PubMed Web of Science ®Google Scholar
• Merle H, Olindo S, Jeannin S, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol. 2012;130:858–862. doi:10.1001/archophthalmol.2012.1126
   PubMedGoogle Scholar
• Zhou Y, Zhong X, Shu Y, et al. Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder. Mult Scler Relat Dis. 2019;28:213–220. doi:10.1016/j.msard.2018.12.038
   Web of Science ®Google Scholar
• Wang J, Zhou H, Qin L, et al. Optic neuritis in the older Chinese population: a 5-year follow-up study. J Ophthalmol. 2017;2017:1–7.
   Web of Science ®Google Scholar
• Chitnis T, Ness J, Krupp L, et al. Clinical features of neuromyelitis optica in children: US network of pediatric MS centers report. Neurology. 2016;86:245–252. doi:10.1212/WNL.0000000000002283
   Web of Science ®Google Scholar
• Hollen C, Suhaib O, Farrow A, et al. Elderly-onset neuromyelitis optica spectrum disorder with pre-existing prednisone allergy. Case Rep Neurol. 2018;10:25–28. doi:10.1159/000485120
   Web of Science ®Google Scholar
• Petzold A, Pittock S, Lennon V, et al. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry. 2009;81:109–111. doi:10.1136/jnnp.2008.146894
   Web of Science ®Google Scholar
• Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses. Ann Neurol. 2016;79:206–216. doi:10.1002/ana.24554
   PubMed Web of Science ®Google Scholar
• Srikajon J, Siritho S, Ngamsombat C, et al. Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis. Mult Scler J Exp Transl Clin. 2018;4(3):1–12.
   Google Scholar
• Ramanathan S, Prelog K, Barnes E, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2015;22:470–482.
   Web of Science ®Google Scholar
• Akaishi T, Takeshita T, Himori N, et al. Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD. Front Neurol. 2020;11:932. doi:10.3389/fneur.2020.00932
   PubMed Web of Science ®Google Scholar